SNGX - SOLIGENIX, INC.
1.19
0.040 3.361%
Share volume: 93,305
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$1.15
0.04
0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-10-2024 | 08-09-2024 | 11-08-2024 | 03-21-2025 | 05-09-2025 | 08-14-2025 | 11-07-2025 | |
| Total revenue | 117.029 K | 2.342 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 117.029 K | 2.342 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 2.117 M | 1.745 M | 1.865 M | 3.712 M | 3.312 M | 2.764 M | 2.580 M | |
| Selling general and admin | 1.022 M | 1.244 M | 896.547 K | 1.054 M | 1.085 M | 1.087 M | 996.604 K | |
| Research and development | 1.095 M | 501.158 K | 968.689 K | 2.659 M | 2.227 M | 1.677 M | 1.584 M | |
| Total expenses | 2.117 M | 1.745 M | 1.865 M | 3.712 M | 3.312 M | 2.764 M | 2.580 M | |
| -17.59% | 6.91% | 99.04% | -10.79% | -16.55% | -6.64% | |||
| Operating income | -2.117 M | -1.745 M | -1.865 M | -3.712 M | -3.312 M | -2.764 M | -2.580 M | |
| Ebit | -1.944 M | -1.680 M | -1.798 M | -3.467 M | -3.313 M | -2.772 M | -2.583 M | |
| Pretax income | -1.915 M | -1.645 M | -1.719 M | -3.396 M | -3.237 M | -2.702 M | -2.531 M | |
| -14.14% | 4.55% | 97.54% | -4.70% | -16.52% | -6.33% | |||
| Income tax | 0.000 | 0.000 | 0.000 | -409.114 K | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -1.915 M | -1.645 M | -1.719 M | -2.987 M | -3.237 M | -2.702 M | -2.531 M | |
| 14.14% | -4.55% | -73.75% | -8.35% | 16.52% | 6.33% |